Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

作者
Karen A. Autio,Valentina Boni,Rachel W. Humphrey,Aung Naing
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (5): 984-989 被引量:183
标识
DOI:10.1158/1078-0432.ccr-19-1457
摘要

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
terryok发布了新的文献求助30
刚刚
1秒前
1秒前
1秒前
1秒前
Chloe完成签到,获得积分10
1秒前
2秒前
3秒前
Yuan88发布了新的文献求助10
3秒前
FashionBoy的应助被cuipi采纳,获得10
3秒前
今后的应助被忧郁的人英采纳,获得10
4秒前
4秒前
4秒前
4秒前
wanci的应助被知性的派大星采纳,获得10
5秒前
Fiszh发布了新的文献求助10
6秒前
星辰大海的应助被星辞采纳,获得10
6秒前
Yuan88发布了新的文献求助10
6秒前
7秒前
7秒前
8秒前
Mmmin完成签到,获得积分10
8秒前
丘比特的应助被flash采纳,获得10
9秒前
Yuan88发布了新的文献求助10
9秒前
9秒前
12秒前
半岛完成签到 ,获得积分10
12秒前
迷人雪一完成签到,获得积分10
12秒前
12秒前
悟生菌完成签到,获得积分10
13秒前
13秒前
Orange的应助被drizzle采纳,获得10
14秒前
Chris学长完成签到,获得积分10
15秒前
15秒前
15秒前
Yuan88发布了新的文献求助10
15秒前
Rn发布了新的文献求助10
16秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784